Business Wire

Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting

SHANGHAI & CAMBRIDGE, Mass. & BAAR, Switzerland--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) and Novocure (NASDAQ: NVCR) announced that results from the Phase 3 PANOVA-3 trial of Tumor ...
The American Journal of Managed Care

From “Super Skeptical” Beginnings, a New Immune-Modulatory Vaccine Awaits Phase 3 Results

IO Biotech's vaccines activate T cells to modify the tumor microenvironment, targeting both cancer and immune-suppressive cells. The T-win technology combines IO102 and IO103, targeting IDO and PD-L1, ...
Nasdaq

Pharvaris Updates Timeline for Topline Data from RAPIDe-3 Phase 3 Study of Deucrictibant for HAE Treatment

Pharvaris, a late-stage biopharmaceutical company focused on developing oral bradykinin B2 receptor antagonists for bradykinin-mediated diseases like hereditary angioedema (HAE), has updated the ...
Business Wire

Veradermics Completes Enrollment in its Phase 2/3 Clinical Trial of VDPHL01 for Male Pattern Hair Loss, Advancing Development of the Potential First-Ever Extended-Release Oral ...

NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated, a dermatologist-founded, late clinical-stage biopharmaceutical company developing potentially first-in-class therapeutics for common ...
Seeking Alpha

Celcuity: Positive Phase 3 Wild-Type ABC Data With Gedatolisib Leads To End Of 2025 Catalyst

Celcuity (CELC) recently released positive results from its phase 3 VIKTORIA-1 trial, which used its drug gedatolisib in combination with other therapies to treat patients with PIK3CA wildtype ...